EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety of Dupilumab in Chinese Elderly Patients with Atopic Dermatitis: A Real-World Study

Yu-Qing Hu, Jian-Zhong Zhang, Yan Zhao

Dermatology · 2024

DOI: 10.1159/000539355 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatology, 2024. Verfasst von Yu-Qing Hu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Peking University People's Hospital, Beijing, China, liuyehujian@163.com. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Severity of Illness Index. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

With the aging of the population in China, the prevalence of atopic dermatitis (AD) is high in elderly patients. These patients usually have more comorbidities and they need more effective and safer treatments. Dupilumab is an anti-interleukin-4 (IL-4) receptor monoclonal antibody which was approved for the treatment of moderate-to-severe AD.

Methods

Elderly patients (60 years or older) with moderate-to-severe AD who treated with dupilumab were included. Eczema Area and Severity Index (EASI) score, Peak Pruritus Numerical Rating Scale (PP-NRS), EASI-50, EASI-75, and EASI-50 were evaluated. The efficacy in subgroups was also investigated.

Results

Fifty-eight patients were enrolled. The EASI score and PP-NRS score were significantly reduced at weeks 4, 16, 28, and 52. 91.2% and 79.4% of the patients achieved EASI-50 and EASI-75 at week 16, respectively. 95.8% and 87.5% patients achieved EASI-50 and EASI-75 at week 52, respectively. Adverse events were reported in 10 (17.2%) patients, and no severe adverse event was reported. Male, older age, and moderate AD (EASI <21) were related to better efficacy.

Conclusions

This study demonstrated that dupilumab is effective and safe in elderly patients with AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedSeverity of Illness IndexHumansMaleFemaleAgedMiddle AgedChinaTreatment OutcomeAged, 80 and overPruritusEast Asian People

Stichwörter der Autor:innen

Atopic dermatitisDupilumabEfficacyElderlySafety

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, Peking University People's Hospital, Beijing, China, liuyehujian@163.com.
  • Department of Dermatology, Peking University People's Hospital, Beijing, China.

Zitieren

APA

Hu, Y. Q., Zhang, J. Z., & Zhao, Y. (2024). Efficacy and Safety of Dupilumab in Chinese Elderly Patients with Atopic Dermatitis: A Real-World Study. Dermatology. https://doi.org/10.1159/000539355

Vancouver

Hu YQ, Zhang JZ, Zhao Y. Efficacy and Safety of Dupilumab in Chinese Elderly Patients with Atopic Dermatitis: A Real-World Study. Dermatology. 2024. doi:10.1159/000539355

BibTeX
@article{Hu2024,
  author = {Hu, Yu-Qing and Zhang, Jian-Zhong and Zhao, Yan},
  title = {Efficacy and Safety of Dupilumab in Chinese Elderly Patients with Atopic Dermatitis: A Real-World Study},
  journal = {Dermatology},
  year = {2024},
  doi = {10.1159/000539355}
}
Kostenlos starten →